Peel, PLI 12 19 23 20 19 reSound OM 5510 for PP reSound OM 5510-60N Room Temperature 70C Bio-derived Content (%) 50% 50% 50% 50% 50% 50% 50% Hardness, Shore A 60 60 60 60 60 60 60 Specific Gravity 0.89 0.89 0.89 0.89 0.89 0.89 0.90 50% Modulus, PSI 247 241 244 251 234 244 240 100% Modulus, PSI 343 333 338 339 321 331 326 Tensile Strength, PSI 625 621 647 610 633 662 642 Elongation, % 306 314 309 313 312 315 315 Tear Strength, PLI 109 108 113 113 111 117 115 reSound OM 5520-55N Room Temperature 70C Bio-derived Content (%) 49% 49% 49% 49% 49% 49% 49% Hardness, Shore A 54 54 55 55 54 55 56 Specific Gravity 0.95 0.95 0.96 0.96 0.95 0.96 0.96 50% Modulus, PSI 258 256 256 265 266 271 257 100% Modulus, PSI 353 355 357 362 373 379 367 Tensile strength, PSI 637 615 637 669 651 674 642 Elongation, % 319 315 319 333 313 319 315 Tear Strength, PLI 146 136 133 142 137 138 141 reSound OM 5510-45N Room Temperature 70C Bio-derived Content (%) 40% 40% 40% 40% 40% 40% 40% Hardness, Shore A 45 46 47 46 46 45 45 Specific Gravity 0.88 0.89 0.89 0.89 0.89 0.89 0.90 50% Modulus, PSI 153 158 154 162 137 136 133 100% Modulus, PSI 251 259 259 261 226 222 218 Tensile Strength, PSI 438 481 451 495 417 470 486 Elongation, % 215 240 211 243 204 227 238 Tear Strength, PLI 84 81 87 82 83 85 84 AGING – PROPERTY RETENTION • Tested at room temperature and 70° C for comparison • Hardness, tensile strength elongation and modulus showed great retention Overmolding onto PP Overmolding onto ABS RHEOLOGY Suitable for injection molding and overmolding 1.0 10 100 1000 10000 100000 10.0 100.0 1000.0 reSound OM 5510-30N reSound OM 5510-45N reSound OM 5510-60N reSound OM 5510-70N Shear Rate, 1/s Ca pi lla ry V is co si ty , P a* s 1.0 10 100 1000 10000 100000 10.0 100.0 1000.0 reSound OM 5520-55N Shear Rate, 1/s Ca pi lla ry V is co si ty , P a* s Capillary viscosity at 200°C Capillary viscosity at 200°C reSound OM 5510 for PP reSound OM 5520 for ABS www.avient.com Copyright © 2020, Avient Corporation.

Toluca, Mexico 81. NOx: 0.09 MT 2. PSIC: 0 2.

Microsoft PowerPoint - Avient March IR - Fermium AVIENT CORPORATION (NYSE: AVNT) M A R C H 1 8 , 2 0 2 1 I R M E E T I N G S H O S T E D B Y F E R M I U M R E S E A R C H DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 24 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Other 2 3 2 2 3 3 3 4 3 3 4 4 4 5 5 5 5 7 7 8 23 t (E xc l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) 85 89 86 86 82 80 76 89 85 83 82 81 78 77 77 76 75 73 70 69 49 19 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is below specialty formulator peers and some of our more highly valued chemical peers.

AVIENT CORPORATION (NYSE: AVNT) N O V E M B E R 2 0 2 0 DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 17 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Other 2 3 2 2 3 3 3 3 4 5 5 5 5 5 6 6 7 7 9 t (E x c l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 82% Median: 73% HIGH FREE CASH FLOW CONVERSION 83 86 85 85 80 78 58 88 83 81 79 77 76 73 73 72 72 67 64 63 60 Net Debt / 2021E EBITDA (1) We typically operate at 2.5–3.0x net debt to EBITDA.

Mevopur Healthcare Functional Additives Medical Devices Application Bulletin_CN12.15-2

PolyOne Corporation Page 1 PolyOne Investor Presentation RW Baird 2015 Industrial Conference November 2015 PolyOne Corporation Page 2 Forward-Looking Statements  In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Platform operating income mix percentage 2005* 2008* 2010* 2013 2014 2015 YTD Global Color, Additives and Inks $ 4.3 $ 28.1 $ 37.7 $104.0 $124.9 $ 107.9 Global Specialty Engineered Materials 0.4 17.6 49.7 57.2 72.4 63.2 Designed Structures and Solutions - - - 33.4 45.1 12.0 Specialty Platform $ 4.7 $ 45.7 $ 87.4 $194.6 $242.4 $ 183.1 Performance Products and Solutions 75.7 31.3 54.0 56.0 63.1 43.9 Distribution 19.5 28.1 42.0 63.3 68.2 52.4 Joint ventures 91.9 28.6 18.9 - - — Corporate and eliminations (51.5) (425.1) (27.7) (82.4) (218.6) (59.8) Operating income (loss) GAAP $140.3 $(291.4) $174.6 $231.5 $155.1 $ 219.6 Less: Corporate operating expense 51.5 425.1 27.7 82.4 218.6 59.8 Operating income excluding Corporate $191.8 $133.7 $202.3 $313.9 $373.7 $ 279.4 Specialty platform operating mix percentage 2% 34% 43% 62% 65% 66% Adjusted EPS is calculated as follows: Adjusted EPS 2006Y* 2007Y* 2008Y* 2009Y* 2010Y 2011Y 2012Y 2013Y 2014Y Net income attributable to PolyOne common shareholders $ 130.9 $ 40.9 $ (417.0) $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 Joint venture equity earnings, after tax (68.5) (26.1) (20.8) (19.0) (14.7) (3.7) - - - Special items, after tax(1) (21.2) 41.4 310.0 (31.0) 15.8 (30.5) 35.7 30.4 101.0 Tax adjustments(2) (30.0) (30.7) 147.2 (44.9) (88.3) (42.3) 0.5 2.2 (10.5) Adjusted net income $ 11.2 $ 25.5 $ 19.4 $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 Diluted shares 92.8 93.1 92.7 93.4 96.0 94.3 89.8 96.5 93.5 Adjusted EPS $ 0.12 $ 0.27 $ 0.21 $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 2 Adjusted EPS 2011 Q3 2012 Q3 2013 Q3 2014 Q3 2015 Q3 Net income attributable to PolyOne common shareholders $ 16.0 $ 19.4 $ 23.2 $ 32.3 $ 44.5 Special items, after tax(1) 3.1 5.3 10.5 13.2 12.6 Tax adjustments(2) (0.3) 0.1 1.8 (0.1) (9.6) Adjusted net income $ 18.8 $ 24.8 $ 35.5 $ 45.4 $ 47.5 Diluted shares 94.3 90.2 98.1 93.1 88.4 Adjusted EPS $ 0.20 $ 0.27 $ 0.36 $ 0.49 $ 0.54 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principal or discontinued operations 2) Tax adjustments include the net tax expense/benefit from one-time income tax items, the set-up or reversal of uncertain tax position reserves and deferred income tax valuations allowance adjustments.

PolyOne Corporation Page 1 PolyOne Investor Presentation Credit Suisse Boston Basic Materials Conference June 2015 PolyOne Corporation Page 2 Forward-Looking Statements  In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. S&P 500 PolyOne Corporation Page 9 2006 Q1 2015 2020 “Where we were” “Where we are” Platinum Vision 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 16.2% 20%+ Global Specialty Engineered Materials 1.1% 16.3% 20%+ Designed Structures & Solutions 1.4% (2012) 2.7% 12 – 14% Performance Products & Solutions 5.5% 6.5% 10 – 12% Distribution 2.6% 5.9% 6.5 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 69% 80%+ 3) ROIC 5.0% 11.4% 15% 4) Adjusted EPS Growth N/A 22 Consecutive Quarters of EPS Growth Double Digit Expansion Proof of Performance & 2020 Goals PolyOne Corporation Page 10 Platinum Vision: Pathway to Accelerated Growth Organic Sales Growth Margin Expansion Share Repurchases Acquisitions PolyOne Corporation Page 11 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years $20 $53 2006 2014 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14% 27% 2006 2014 Specialty Platform Gross Margin % 20% 44% 2006 2014 Specialty Vitality Index Target ≥ 35% PolyOne Corporation Page 12 Megatrends Aligned with Key End Markets Decreasing Dependence on Fossil Fuels Protecting the Environment Improving Health and Wellness Megatrend End Markets Globalizing and Localizing Health & Wellness Transportation Packaging Consumer PolyOne Corporation Page 13 Prototype Frame Opportunity Scale-up & Test Market Build Business Case Commercial Launch Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 6 9 7 3 5 12 5 3 2 8 4 2 4 3 1 Breakthrough Platform Derivative A Rich Pipeline of Opportunity Number of Projects 14 8 18 12 22 74 Addressable Market ($ millions) $700 $600 $600 $1,900 PolyOne Corporation Page 14 60% 98% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 Q1 2015 Pension Funding** As of March 31, 2015 Debt Maturities & Pension Funding Net Debt / EBITDA* = 2.1x $49 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2015 ($ millions) Coupon Rate: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 3/31/2015 PolyOne Corporation Page 15 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return  Expanding our sales, marketing, and technical capabilities  Investing in operational and LSS initiatives  ~75% of capital expenditures fund growth initiatives Organic Growth Acquisitions Share Repurchases Dividends $0.16 $0.20 $0.24 $0.32 $0.40 $0.10 $0.20 $0.30 $0.40 $0.50 2011 2012 2013 2014 2015 Annual Dividend  Targets that expand our: • Specialty offerings • End market presence • Geographic breadth  Synergy opportunities  Adjacent material solutions  Repurchased over 500k shares in Q1 2015  Repurchased 11.8 million shares since early 2013  8.2 million shares are available for repurchase under the current authorization PolyOne Corporation Page 16 PolyOne Core Values Innovation Collaboration Excellence PolyOne Corporation Page 17 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne? Adjusted EPS 2006Y* 2007Y* 2008Y* 2009Y* 2010Y 2011Y 2012Y 2013Y 2014Y Net income attributable to PolyOne common shareholders $ 130.9 $ 40.9 $ (417.0) $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 Joint venture equity earnings, after tax (68.5) (26.1) (20.8) (19.0) (14.7) (3.7) - - - Special items, after tax(1) (21.2) 41.4 310.0 (31.0) 15.8 (30.5) 35.7 30.4 101.0 Tax adjustments(2) (30.0) (30.7) 147.2 (44.9) (88.3) (42.3) 0.5 2.2 (10.5) Adjusted net income $ 11.2 $ 25.5 $ 19.4 $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 Diluted shares 92.8 93.1 92.7 93.4 96.0 94.3 89.8 96.5 93.5 Adjusted EPS $ 0.12 $ 0.27 $ 0.21 $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 Adjusted EPS 2010 Q1 2011 Q1 2012 Q1 2013 Q1 2014 Q1 2015 Q1 Net income attributable to PolyOne common shareholders $ 20.1 $ 106.0 $ 15.3 $ 11.2 $ 29.4 $ 30.2 Joint venture equity earnings, after tax (0.5) (3.7) - - - - Special items, after tax(1) (0.3) (79.8) 6.1 17.2 14.1 5.5 Tax adjustments(2) (3.5) (1.5) 0.1 0.5 (1.6) 5.9 Adjusted net income $ 15.8 $ 21.0 $ 21.5 $ 28.9 $ 41.9 $ 41.6 Diluted shares 95.3 96.4 90.7 92.8 95.7 90.1 Adjusted EPS $ 0.17 $ 0.22 $ 0.24 $ 0.31 $ 0.44 $ 0.46 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principal or discontinued operations

AVIENT CORPORATION I N V E S T O R P R E S E N T A T I O N (NYSE: AVNT) N OV E M B E R 2 0 2 3 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Additionally, Adjusted EPS excludes the impact of special items and amortization expense associated with intangible assets. 2 3 AVIENT OVERVIEW OUR VISION: Creating specialized and sustainable material solutions that transform customer challenges into opportunities, bringing new products to life for a better world 2023 Financial GuidanceCompany Overview Revenue By: 9,700 Employees 104 Manufacturing Sites 20,000+ Customers Key Highlights  Premier formulator of specialized and sustainable material solutions  Asset-light business model, with flexibility to adapt to customer needs  Best-in-class technology and service (140+ PhDs / 2,500+ patents)  History of transformation through successful M&A while consistently returning cash to shareholders  Poised for continued future growth in excess of GDP $3.13B Revenue $500M Adjusted EBITDA Adjusted EBITDA Margins $180M Free Cash Flow Over $1B in share buybacks since 2011 Raised dividend for 13 consecutive years, a 15% CAGR since 2011 U.S. & Canada 64% 36% Specialty Engineered Materials Color Additives and Inks 40% 37% 18% 9% 4% 4% Building & Energy Telecom Geography Segment Industry 4 CREATING A WORLD-CLASS SUSTAINABLE ORGANIZATION 1. 6% annualized long term sales growth leveraging sustainable solutions, composites, healthcare and emerging regions 2. Avient reflects 2023 adjusted EBITDA guidance of $500M and estimated run-rate CAPEX of $110M. 2023E (%) 27 78 89 84 82 80 77 88 81 76 70 69 60 54 (6) Av ie nt PP PM FM C C Avient Specialty Other Specialty / MULTIPLE EXPANSION Note: Avient reflects 2023 adjusted EBITDA guidance of $500M and closing share price of $31.18.